US5021422A
(en)
*
|
1989-06-08 |
1991-06-04 |
Senetek Plc |
Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins
|
GB9020959D0
(en)
*
|
1990-09-26 |
1990-11-07 |
Beecham Group Plc |
Novel compounds
|
GB9020921D0
(en)
*
|
1990-09-26 |
1990-11-07 |
Beecham Group Plc |
Novel compounds
|
NZ240644A
(en)
*
|
1990-11-21 |
1994-08-26 |
Smithkline Beecham Corp |
Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
|
WO1992011260A1
(en)
*
|
1990-12-21 |
1992-07-09 |
Beecham Group Plc |
Xanthine derivatives
|
EP0593567B1
(de)
|
1991-07-05 |
1996-08-28 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Verwendung substituierter pyridazine gegen dermatosen
|
WO1993016699A1
(en)
*
|
1992-02-21 |
1993-09-02 |
Smithkline Beecham Corporation |
Tnf inhibitors
|
US5342841A
(en)
*
|
1992-03-12 |
1994-08-30 |
Kyowa Hakko Kogyo Co., Ltd. |
Xanthine derivatives
|
CA2093403C
(en)
*
|
1992-04-08 |
1999-08-10 |
Fumio Suzuki |
Therapeutic agent for parkinson's disease
|
GB9210839D0
(en)
*
|
1992-05-21 |
1992-07-08 |
Smithkline Beecham Plc |
Novel compounds
|
GB9215633D0
(en)
*
|
1992-07-23 |
1992-09-09 |
Smithkline Beecham Plc |
Novel treatment
|
US6469017B1
(en)
*
|
1998-01-16 |
2002-10-22 |
Cell Therapeutics, Inc. |
Method of inhibiting interleukin-12 signaling
|
US6693105B1
(en)
|
1992-11-16 |
2004-02-17 |
Cell Therapeutics, Inc. |
Hydroxyl-containing compounds
|
GB9312853D0
(en)
|
1993-06-22 |
1993-08-04 |
Euro Celtique Sa |
Chemical compounds
|
US6878715B1
(en)
*
|
1994-02-18 |
2005-04-12 |
Cell Therapeutics, Inc. |
Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
|
US5646156A
(en)
*
|
1994-04-25 |
1997-07-08 |
Merck & Co., Inc. |
Inhibition of eosinophil activation through A3 adenosine receptor antagonism
|
US5922751A
(en)
|
1994-06-24 |
1999-07-13 |
Euro-Celtique, S.A. |
Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
|
US5591776A
(en)
|
1994-06-24 |
1997-01-07 |
Euro-Celtique, S.A. |
Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
|
EP0799040B1
(en)
|
1994-12-13 |
2003-08-20 |
Euroceltique S.A. |
Trisubstituted thioxanthines
|
JPH10508032A
(ja)
|
1994-12-13 |
1998-08-04 |
ユーロ−セルティーク,エス.エイ. |
アリールチオキサンチン類
|
CA2218548A1
(en)
*
|
1995-05-19 |
1996-11-21 |
Chiroscience Limited |
Xanthines and their therapeutic use
|
US6166041A
(en)
|
1995-10-11 |
2000-12-26 |
Euro-Celtique, S.A. |
2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
|
US6075016A
(en)
|
1996-04-10 |
2000-06-13 |
Euro-Celtique S.A. |
6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
|
US5864037A
(en)
*
|
1996-06-06 |
1999-01-26 |
Euro-Celtique, S.A. |
Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
GB9623859D0
(en)
*
|
1996-11-15 |
1997-01-08 |
Chiroscience Ltd |
Novel compounds
|
GB9703044D0
(en)
|
1997-02-14 |
1997-04-02 |
Glaxo Group Ltd |
Phenyl xanthine esters and amides
|
DE69834500T2
(de)
|
1997-09-05 |
2007-05-03 |
Kyowa Hakko Kogyo Co., Ltd. |
Xanthinderivative zur behandlung von hirnischämie
|
MA24682A1
(fr)
|
1997-10-23 |
1999-07-01 |
Smithkline Beecham Corp |
Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
|
GB9817623D0
(en)
|
1998-08-13 |
1998-10-07 |
Glaxo Group Ltd |
Pharmaceutical compounds
|
SK287231B6
(sk)
|
1999-08-21 |
2010-04-07 |
Nycomed Gmbh |
Liečivo zahŕňajúce PDE inhibítor a agonistu beta2 adrenoreceptora
|
US6555572B2
(en)
*
|
2000-03-16 |
2003-04-29 |
Inflazyme Pharmaceuticals Ltd. |
Benzylated PDE4 inhibitors
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
US6586429B2
(en)
|
2000-11-29 |
2003-07-01 |
Cell Therapeutics, Inc. |
Tricyclic fused xanthine compounds and their uses
|
PT1368349E
(pt)
*
|
2001-02-24 |
2007-04-30 |
Boehringer Ingelheim Pharma |
Derivados de xantina, sua preparação e sua utilização como medicamento
|
DE60228073D1
(de)
*
|
2001-05-08 |
2008-09-18 |
Brni Neurosciences Inst |
Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
|
US6825180B2
(en)
|
2001-05-18 |
2004-11-30 |
Cell Therapeutics, Inc. |
Pyridopyrimidine compounds and their uses
|
AU2002333193A1
(en)
*
|
2001-08-15 |
2003-03-03 |
Leo Pharma A/S |
A pharmaceutical composition for dermal application
|
CA2457944C
(en)
|
2001-08-28 |
2009-09-29 |
Schering Corporation |
Polycyclic guanine phosphodiesterase v inhibitors
|
WO2003042216A1
(en)
|
2001-11-09 |
2003-05-22 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase v inhibitors
|
US20030175314A1
(en)
*
|
2001-11-19 |
2003-09-18 |
Didriksen Erik Johannes |
Pharmaceutical composition for dermal application
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
BRPI0409229A
(pt)
|
2003-04-01 |
2006-03-28 |
Applied Research Systems |
inibidores das fosfodiesterases na infertilidade
|
EP1648895B1
(en)
*
|
2003-07-31 |
2007-05-30 |
Schering Corporation |
Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
|
AU2004296137A1
(en)
*
|
2003-12-09 |
2005-06-23 |
Kyowa Hakko Kirin Co., Ltd. |
Preventive and/or therapeutic agent for higher brain dysfunction
|
KR101100601B1
(ko)
*
|
2004-02-14 |
2011-12-29 |
글락소스미스클라인 엘엘씨 |
신규 화합물
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
JP2009504592A
(ja)
|
2005-08-10 |
2009-02-05 |
スミスクライン・ビーチャム・コーポレイション |
選択的hm74aアゴニストとしてのキサンチン誘導体
|
JP2009533330A
(ja)
*
|
2006-03-21 |
2009-09-17 |
ドクター レディズ ラボラトリーズ リミテッド |
ドセタキセルの多形体およびプロセス
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
MX2008014024A
(es)
|
2006-05-04 |
2008-11-14 |
Boehringer Ingelheim Int |
Formas poliformas.
|
WO2008017670A1
(en)
|
2006-08-08 |
2008-02-14 |
Boehringer Ingelheim International Gmbh |
Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
CA2688161C
(en)
|
2007-06-04 |
2020-10-20 |
Kunwar Shailubhai |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8871751B2
(en)
*
|
2008-01-18 |
2014-10-28 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
CN107011345A
(zh)
|
2008-12-23 |
2017-08-04 |
勃林格殷格翰国际有限公司 |
有机化合物的盐形式
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
EP3646859A1
(en)
|
2009-11-27 |
2020-05-06 |
Boehringer Ingelheim International GmbH |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
AU2011249722B2
(en)
|
2010-05-05 |
2015-09-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
BR112012032579B1
(pt)
|
2010-06-24 |
2021-05-11 |
Boehringer Ingelheim International Gmbh |
uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
CN108676076A
(zh)
|
2011-03-01 |
2018-10-19 |
辛纳吉制药公司 |
制备鸟苷酸环化酶c激动剂的方法
|
HUE043540T2
(hu)
|
2011-07-15 |
2019-08-28 |
Boehringer Ingelheim Int |
Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP3685839A1
(en)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin for use in the treatment of albuminuria and kidney related diseases
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2014131024A2
(en)
|
2013-02-25 |
2014-08-28 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
MX2016001714A
(es)
|
2013-08-09 |
2016-10-03 |
Ardelyx Inc |
Compuestos y metodos para inhibir el transporte de fosfato.
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
SG10201907026RA
(en)
|
2015-01-30 |
2019-09-27 |
Shanton Pharma Co Ltd |
Prevention or Treatment of Uratic or Gouty Diseases
|
PT3280417T
(pt)
|
2015-04-08 |
2020-10-30 |
Lewis And Clark Pharmaceuticals Inc |
Carbamatos de alquinilo substituídos com xantina/carbamatos reversos utilizados como antagonistas de adenosina a2b
|
EP3165224A1
(en)
|
2015-11-09 |
2017-05-10 |
Albert-Ludwigs-Universität Freiburg |
Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
|
WO2017089347A1
(en)
|
2015-11-25 |
2017-06-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
|
BR112018072401A2
(pt)
|
2016-06-10 |
2019-02-19 |
Boehringer Ingelheim International Gmbh |
combinações de linagliptina e metformina
|
WO2020237096A1
(en)
|
2019-05-21 |
2020-11-26 |
Ardelyx, Inc. |
Combination for lowering serum phosphate in a patient
|